Ironwood Pharma (IRWD) Tops Q3 EPS by 6c; Trims Cash Burn Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) Following 3Q Beat
November 4, 2016 7:38 AM EDTMizuho Securities reiterated a Buy rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $20.00 (from $19.00), following the company's 3Q earnings report. IRWD reported revenues of $66.1M and a loss of ($0.18) vs. StreetAccount consensus of $59.8M and ($0.24).
Analyst Irina... More
